A Double-Blind, Randomized, Placebo-controlled, 3-Way Cross Over Study to Evaluate the Efficacy and Safety of 14 Days TPI ASM8 in Subjects With Asthma.
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2012
At a glance
- Drugs ASM 8 (Primary)
- Indications Allergic asthma
- Focus Biomarker; Therapeutic Use
- 02 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Sep 2011 Results of this trial are anticipated in the second quarter of 2012, according to a Pharmaxis media release.
- 29 Sep 2011 Pharmaxis confirms the completion of patient enrolment in a company media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History